CN104470913B - 用于制造羟基化的环戊基嘧啶化合物的方法 - Google Patents
用于制造羟基化的环戊基嘧啶化合物的方法 Download PDFInfo
- Publication number
- CN104470913B CN104470913B CN201380038057.4A CN201380038057A CN104470913B CN 104470913 B CN104470913 B CN 104470913B CN 201380038057 A CN201380038057 A CN 201380038057A CN 104470913 B CN104470913 B CN 104470913B
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- alkyl
- substituted
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](C*)c1c(*)ncnc1* Chemical compound C[C@](C*)c1c(*)ncnc1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648473P | 2012-05-17 | 2012-05-17 | |
| US61/648,473 | 2012-05-17 | ||
| US201361785122P | 2013-03-14 | 2013-03-14 | |
| US61/785,122 | 2013-03-14 | ||
| PCT/US2013/041666 WO2013173768A1 (en) | 2012-05-17 | 2013-05-17 | Process for making hydroxylated cyclopentylpyrimidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104470913A CN104470913A (zh) | 2015-03-25 |
| CN104470913B true CN104470913B (zh) | 2018-07-20 |
Family
ID=48485537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380038057.4A Active CN104470913B (zh) | 2012-05-17 | 2013-05-17 | 用于制造羟基化的环戊基嘧啶化合物的方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9416110B2 (enExample) |
| EP (1) | EP2861582B1 (enExample) |
| JP (1) | JP6284928B2 (enExample) |
| KR (1) | KR102067850B1 (enExample) |
| CN (1) | CN104470913B (enExample) |
| AU (1) | AU2013262505B2 (enExample) |
| BR (1) | BR112014028589B1 (enExample) |
| CA (1) | CA2873654C (enExample) |
| DK (1) | DK2861582T3 (enExample) |
| ES (1) | ES2582557T3 (enExample) |
| IL (1) | IL235715A (enExample) |
| MX (1) | MX353384B (enExample) |
| MY (1) | MY169028A (enExample) |
| NZ (1) | NZ702935A (enExample) |
| PL (1) | PL2861582T3 (enExample) |
| RU (1) | RU2643811C2 (enExample) |
| SG (1) | SG11201407616TA (enExample) |
| SI (1) | SI2861582T1 (enExample) |
| WO (1) | WO2013173768A1 (enExample) |
| ZA (1) | ZA201409261B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173736A1 (en) | 2012-05-17 | 2013-11-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| PE20150725A1 (es) | 2012-05-17 | 2015-05-17 | Genentech Inc | Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| CA2873654C (en) | 2012-05-17 | 2021-06-22 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| ES2957314T3 (es) | 2013-11-15 | 2024-01-17 | Hoffmann La Roche | Procesos para la preparación de compuestos de pirimidinilciclopentano |
| SG11201702324QA (en) * | 2014-09-26 | 2017-04-27 | Hoffmann La Roche | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS |
| CN109789141B (zh) | 2016-08-10 | 2022-08-26 | 豪夫迈·罗氏有限公司 | 包含Akt蛋白激酶抑制剂的药物组合物 |
| MX2022015322A (es) | 2020-06-16 | 2023-01-11 | Hoffmann La Roche | Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada. |
| KR102689151B1 (ko) * | 2021-09-06 | 2024-07-29 | 연세대학교 산학협력단 | Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188754A1 (en) * | 1999-06-03 | 2002-03-20 | Teikoku Hormone Mfg. Co., Ltd. | Substituted pyrazole compounds |
| WO2008006040A1 (en) * | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1134212C (zh) | 1993-12-12 | 2004-01-14 | 阿格罗吉恩有限公司 | 保护植物免受真菌侵染的新方法 |
| AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
| US6376496B1 (en) | 1999-03-03 | 2002-04-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| WO2004108673A2 (en) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibitors of papilloma virus |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| CA2758484A1 (en) | 2009-04-15 | 2010-10-21 | David A. Degoey | Anti-viral compounds |
| JP5581390B2 (ja) * | 2009-10-23 | 2014-08-27 | イーライ リリー アンド カンパニー | Ａｋｔ阻害剤 |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| WO2012177925A1 (en) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| PE20150725A1 (es) | 2012-05-17 | 2015-05-17 | Genentech Inc | Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este |
| CA2873658C (en) | 2012-05-17 | 2021-01-26 | Genentech, Inc. | Process for making amino acid compounds |
| CA2873654C (en) | 2012-05-17 | 2021-06-22 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| WO2013173736A1 (en) | 2012-05-17 | 2013-11-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| NZ702950A (en) | 2012-05-17 | 2016-09-30 | Genentech Inc | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| US20140121193A1 (en) | 2012-11-01 | 2014-05-01 | Robert S. Katz | Methods for treating fibromyalgia |
| EP2956441A4 (en) | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
| US10131637B2 (en) | 2013-03-15 | 2018-11-20 | Shifa Biomedical Corporation | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
-
2013
- 2013-05-17 CA CA2873654A patent/CA2873654C/en active Active
- 2013-05-17 DK DK13725042.9T patent/DK2861582T3/en active
- 2013-05-17 RU RU2014151050A patent/RU2643811C2/ru active
- 2013-05-17 US US14/401,087 patent/US9416110B2/en active Active
- 2013-05-17 BR BR112014028589-6A patent/BR112014028589B1/pt active IP Right Grant
- 2013-05-17 JP JP2015512900A patent/JP6284928B2/ja active Active
- 2013-05-17 MY MYPI2014703415A patent/MY169028A/en unknown
- 2013-05-17 PL PL13725042.9T patent/PL2861582T3/pl unknown
- 2013-05-17 MX MX2014013862A patent/MX353384B/es active IP Right Grant
- 2013-05-17 SI SI201330261A patent/SI2861582T1/sl unknown
- 2013-05-17 KR KR1020147035427A patent/KR102067850B1/ko active Active
- 2013-05-17 ES ES13725042.9T patent/ES2582557T3/es active Active
- 2013-05-17 AU AU2013262505A patent/AU2013262505B2/en active Active
- 2013-05-17 EP EP13725042.9A patent/EP2861582B1/en active Active
- 2013-05-17 SG SG11201407616TA patent/SG11201407616TA/en unknown
- 2013-05-17 NZ NZ702935A patent/NZ702935A/en not_active IP Right Cessation
- 2013-05-17 CN CN201380038057.4A patent/CN104470913B/zh active Active
- 2013-05-17 WO PCT/US2013/041666 patent/WO2013173768A1/en not_active Ceased
-
2014
- 2014-11-13 IL IL235715A patent/IL235715A/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09261A patent/ZA201409261B/en unknown
-
2016
- 2016-07-07 US US15/204,715 patent/US9676730B2/en active Active
-
2017
- 2017-05-11 US US15/593,064 patent/US9790190B2/en active Active
- 2017-10-12 US US15/782,620 patent/US20180258054A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188754A1 (en) * | 1999-06-03 | 2002-03-20 | Teikoku Hormone Mfg. Co., Ltd. | Substituted pyrazole compounds |
| WO2008006040A1 (en) * | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470913B (zh) | 用于制造羟基化的环戊基嘧啶化合物的方法 | |
| CA2958139A1 (en) | Solid state forms of ibrutinib | |
| KR20120097508A (ko) | 벤조디아제핀 브로모도메인 억제제 | |
| CN106977415A (zh) | 一种沙库必曲的中间体及其制备方法 | |
| KR20170131508A (ko) | 레디파스비르 및 이의 유도체의 제조방법 및 레디파스비르를 제조하기 위한 중간체 화합물 | |
| AU2018366342A1 (en) | Method for preparing Baricitinib | |
| WO2009046624A1 (en) | Preparation methods of (4s,5r)-semi-esters | |
| KR102074535B1 (ko) | 아미노산 화합물의 제조 방법 | |
| CN112088003B (zh) | 制备嘧啶基-4-氨基吡唑化合物的工艺 | |
| JP5159630B2 (ja) | 縮環複素環誘導体 | |
| CN107001287A (zh) | 用于制备(环戊并[d]嘧啶‑4‑基)哌嗪化合物的方法 | |
| CN103373973A (zh) | 新的左西替利嗪合成工艺及其关键中间体 | |
| CN120659780A (zh) | 嘧啶氨基吡唑化合物的制备方法和中间体 | |
| HK1208451B (zh) | 用於製造羥基化的環戊基嘧啶化合物的方法 | |
| CA3155177A1 (en) | Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine | |
| CN121064205A (zh) | 一类溴结构域抑制活性的化合物及其用途 | |
| JP2024511422A (ja) | ５－｛５－クロロ－２－［（３ｓ）－３－［（モルホリン－４－イル）メチル］－３，４－ジヒドロイソキノリン－２（１ｈ）－カルボニル］フェニル｝－１，２－ジメチル－１ｈ－ピロール－３－カルボン酸誘導体を合成するための新規な製造方法及び医薬化合物を製造するためのその適用 | |
| HK40039340A (en) | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| HK40039340B (en) | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| HK1208857B (en) | Process for making amino acid compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1208451 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |